Increases in Autoantibody Level Associated with Degenerative Changes in the Intestinal Mucosa in Liver Cirrhosis

Figures & data

Table 1 The Number of Patients with EPV Before and After Cryoprecipitate Introduction

Number of Patients	EPV in EGD
	1 Stage	2 Stage	3 Stage
Before treatment	5	21	7
After treatment	8*	22	3*

Note: *р≤0.05.

Abbreviations: EPV, esophageal protuberant varicosities; EGD, esophagogastroduodenoscopy.

Table 2 The Number of Patients the Risk of Bleeding from EPV Before and After Cryoprecipitate Introduction

Number of Patients	Portal Blood Flow Rates
	SI		SPI
	Less 0.1	More 0.1	Less 51%	51–100%	More 100%
Before treatment	29	7	8	19	9
After treatment	32*	4 *	12 *	21	3*

Note: *р≤0.05.

Abbreviations: SI, stagnation index; SPI, splenoportal index.

Table 3 Hepatic Blood Flow Rate Changes in Patients with Liver Cirrhosis Before and After Cryoprecipitate Introduction

Sign	D (Mean ± SD) (Portal Vein)	D (Mean ± SD) (Splenic Vein)	LBV (Mean ± SD) (Portal Vein)	LBV (Mean ± SD) (Splenic Vein)
Before treatment	1.5 ±0.3 cm	0.95 ±0.23 cm	10 ±2.2 cm/s	13±1.5 cm/s
After treatment	0.91±0.22 cm *	0.7±0.15 cm *	19 ± 0.5 cm/s *	17.7 ±5.5 cm/s *

Note: *р≤0.05.

Abbreviations: D, diameter; LBV, maximum linear blood flow velocity.

Table 4 The results of Morphological Examination of the Intestinal Wall in Patients with Liver Cirrhosis Before and After Cryoprecipitate Introduction

Sign	Before	After
Edema of proper mucous plate	12	11
Mucosa atrophy	6	17 *
Vessels diameter increase with thickening of the walls	4	4
Neutrophil infiltration	6	9*
Lymphocytic-histiocytic infiltration	5	8
No pathology	18	8 *

Note: *р≤0.05.

Figure 1 Result of morphological examination of the intestinal wall in patients with cirrhosis of the liver tissue before (A) and after (B) cryoprecipitate introduction. Thickening of walls and increase of diameter of vessels (arrows) in intestinal wall (original magnification x400, coloring with hematoxylin-eosin).

Figure 2 Autoantibody values for the small intestine and large intestine antigens in patients with liver cirrhosis.